kiora pharmaceuticals reports results of annual shareholder meeting

Published 04/06/2025, 19:44
kiora pharmaceuticals reports results of annual shareholder meeting

Today, Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), a $10 million market cap biotech company, announced the results of its annual shareholder meeting. The meeting, held in Encinitas, California, saw shareholders vote on several key proposals. According to InvestingPro data, the company’s stock has shown strong momentum with a 30% return over the past week, though it remains significantly below its 52-week high of $5.55.

The election of Carmine Stengone and Brian M. Strem, Ph.D. as Class I Directors was confirmed. Both directors will serve a three-year term, continuing until the 2028 annual meeting or until their successors are elected and qualified. The voting results showed 1,155,217 votes in favor of Stengone and 1,156,954 for Strem, with 80,548 and 78,811 votes withheld, respectively. There were 411,877 broker non-votes for each candidate. The directors face significant challenges ahead, as InvestingPro analysis indicates the company is quickly burning through cash despite maintaining more cash than debt on its balance sheet.

Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. The vote resulted in 1,144,829 votes in favor, 82,389 against, and 8,547 abstentions. Additionally, there were 411,877 broker non-votes.

Furthermore, the appointment of Haskell & White LLP as Kiora Pharmaceuticals’ independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The vote tallied 1,567,427 votes in favor, 78,598 against, and 1,617 abstentions, with no broker non-votes recorded.

This information is based on a press release statement and the official SEC filing of the company.

In other recent news, Kiora Pharmaceuticals has announced a significant deal with Senju Pharmaceutical (TADAWUL:2070) Co., Ltd., potentially valued at $110 million. This exclusive option agreement focuses on the development and commercialization of KIO-301, a treatment for ophthalmic diseases, in Asian markets such as Japan and China. As part of the agreement, Senju has already paid Kiora a $1.25 million option fee, with additional payments contingent on further developments. The deal includes milestones related to development, regulatory, and commercial achievements, alongside tiered royalties on sales. This collaboration is contingent upon the results of the ongoing ABACUS-2 Phase 2 clinical trial for KIO-301. If Senju exercises the option, it will assume responsibility for all activities in the licensed territories. This partnership with Senju builds on Kiora’s existing global partnership with Théa Open Innovation, excluding Asia, and could significantly bolster Kiora’s financial standing. The agreement is expected to extend Kiora’s cash runway into late 2027, surpassing the projected outcomes of two ongoing Phase 2 clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.